Episode Details

New real-world data suggest that GLP-1 receptor agonists used for adolescent obesity are associated with roughly half the rate of asthma exacerbations, fewer emergency visits, and reduced steroid and rescue inhaler use, indicating a possible dual benefit beyond weight loss. In HIV care, Phase 3 ARTISTRY-2 topline results show a once-daily bictegravir/lenacapavir tablet was non-inferior to Biktarvy at 48 weeks, with no new safety signals, potentially expanding durable treatment options. Finally, experimental data demonstrate that even a single 10-minute bout of vigorous exercise can rapidly trigger molecular changes that suppress pathways linked to colon cancer development.